Unity Biotechnology GAAP EPS of -$0.43 misses by $0.03

• Unity Biotechnology press release (NASDAQ:UBX): Q1 GAAP EPS of -$0.43 misses by $0.03.
• Cash, cash equivalents and marketable securities totaled $16.9 million as of March 31, 2025. UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the fourth quarter of 2025.

More on Unity Biotechnology

• UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial
• Seeking Alpha’s Quant Rating on Unity Biotechnology
• Historical earnings data for Unity Biotechnology
• Financial information for Unity Biotechnology